期刊
TRANSLATIONAL ONCOLOGY
卷 39, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2023.101793
关键词
PD-L1; Glioma; Immunotherapy; Immune checkpoint
类别
This article reviews the unsatisfactory results of PD-1/PD-L1 inhibitors in high grade glioma treatment, and discusses the current status of predictive biomarkers and emerging strategies, as well as the clinical significance and therapeutic strategies of the immune checkpoint B7-H4 in pre-clinical glioma models.
Co-inhibitory immune checkpoints play a crucial role in tumor progression, and PD-1/PD-L1 inhibitor has been a breakthrough for treating multiple refractory tumors in last decade. Nevertheless, results of several phase III clinical trials of PD-1/PD-L1 inhibitor are unsatisfactory in high grade gliomas recently. This article reviews the promising biomarkers which can predict the efficacy of PD-1/PD-L1 blockade immunotherapy and current status of emerging strategies involving PD-1/PD-L1 inhibitors, especially the combination treatment and neoadjuvant PD-1 therapy in gliomas. In addition, B7-H4, one of the most promising immune checkpoints, is also briefly reviewed here for its clinical significance, regulatory mechanism and developing immunotherapeutic strategies in pre-clinical glioma models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据